Vesalius Biocapital leads €15 million Series C round of HepaRegeniX

Tübingen/ Berlin — YPOG provi­ded compre­hen­sive legal advice to the lead inves­tor Vesa­lius Bioca­pi­tal IV in the € 15 million Series C finan­cing round of Hepa­Re­ge­niX GmbH. Exis­ting inves­tors such as Novo Holdings, Boeh­rin­ger Ingel­heim Venture Fund and High-Tech Grün­der­fonds also parti­ci­pa­ted in the investment.

Hepa­Re­ge­niX GmbH is a company in the field of clini­cal deve­lo­p­ment of novel thera­pies for the treat­ment of acute and chro­nic liver dise­a­ses. Since its launch in 2017, Hepa­Re­ge­niX has successfully disco­vered and deve­lo­ped seve­ral drug candi­da­tes for the treat­ment of acute and chro­nic liver dise­a­ses based on a novel mole­cu­lar target Mitogen-Acti­­va­­ted Protein (MAP) Kinase Kinase 4 (MKK4). HRX-215 is a small mole­cule inhi­bi­tor of mitogen-acti­­va­­ted protein (MAP) kinase kinase 4 (MKK4). This subs­tance has the poten­tial to signi­fi­cantly support liver rege­ne­ra­tion in pati­ents with liver meta­sta­ses or primary liver tumors.

The new funding will support the Phase Ib/IIa clini­cal trial, which will focus on impro­ving liver heal­ing and preven­ting liver failure.

Advi­sor to Hepa­Re­ge­niX: YPOG

Dr. Martin Scha­per (Lead, Tran­sac­tions), Part­ner, Berlin, Dr. Lutz Schrei­ber (IP/IT/Data Protec­tion), Part­ner, Hamburg, Benja­min Müller (Tran­sac­tions), Asso­ciate, Berlin, Matthias Treude (IP/IT/Data Protec­tion), Asso­ciate, Hamburg, Cyra Ditt­ber­ner (Tran­sac­tions), Asso­ciate, Berlin

About Vesa­lius Bioca­pi­tal IV

Vesa­lius Bioca­pi­tal is an estab­lished Euro­pean life scien­ces venture capi­tal inves­tor with a long track record of consis­tent returns, inves­t­ing in the best/­­first-class Euro­pean biopharma and health­tech companies.

The company invests in attrac­tive compa­nies at an advan­ced stage of deve­lo­p­ment in the fields of drug deve­lo­p­ment, medi­cal tech­no­logy and diagno­stics as well as eHealth/mHealth, prima­rily in Europe. The port­fo­lio compa­nies address unmet medi­cal and market needs and operate on the basis of strong intellec­tual property protection.

About YPOG

YPOG is a law firm specia­li­zing in tax and commer­cial law, active in the core areas of funds, tax, banking + finance and tran­sac­tions. The YPOG team advi­ses a wide variety of clients. These include emer­ging tech­no­logy compa­nies and family-run medium-sized enter­pri­ses as well as corpo­ra­ti­ons and private equity/venture capi­tal funds. YPOG is one of the leading addres­ses for venture capi­tal, private equity and fund struc­tu­ring in Germany. The firm and its part­ners are ranked natio­nally and inter­na­tio­nally by JUVE, Best Lawy­ers, Legal 500, Focus, Cham­bers and Part­ners and Leaders League. Today, YPOG employs more than 120 expe­ri­en­ced lawy­ers, tax consul­tants, tax specia­lists and a notary in three offices in Berlin, Hamburg and Colo­gne. http://www.ypog.law